Most Read Articles
2 days ago
The absence of the classical symptom of chest pain in patients with acute myocardial infarction (AMI) appears to be associated with more complications and higher short- and long-term mortality rates, particularly in younger and healthier patients, according to a study.

Beyond angina relief – Optimizing management of CAD with VASTAREL® MR®

08 Nov 2017
Available in Europe since 1978, trimetazidine was launched in Malaysia in 1986 as VASTAREL® 20, with the first box of this medication sold in 1987. At that time, this agent was available as three times daily dosing; this was soon followed by the modified-release formulation, ie, VASTAREL® MR®, launched in 2005 to simplify the dosing regimen. By 2007, VASTAREL® MR® had become widely available in public hospitals throughout Malaysia.The efficacy of trimetazidine in coronary artery disease (CAD) is well established – it is a well-tolerated anti-ischaemic agent with no effect on blood pressure or heart rate. It is also recommended by Malaysian and international guidelines for symptomatic relief of angina. In conjunction with the 30th anniversary of VASTAREL®, renowned local and international opinion leaders gathered at a Servier symposium, chaired by Dr Jeyamalar Rajadurai, to reflect on the evolution of CAD management and the contemporary role of trimetazidine.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
The absence of the classical symptom of chest pain in patients with acute myocardial infarction (AMI) appears to be associated with more complications and higher short- and long-term mortality rates, particularly in younger and healthier patients, according to a study.